New antibody drug shows promise in fighting advanced cancers
NCT ID NCT04452955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and whether tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRL3-zumab
What this could lead to
If successful, this could provide a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early Phase 2 trial with only 51 participants, so results may not apply to all patients. The drug may not shrink tumors or improve survival, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89014, United States
-
HonorHealth Research
Scottsdale, Arizona, 85258, United States
-
Norton Healthcare
Louisville, Kentucky, 40200, United States
-
St. Jude Medical Center
Fullerton, California, 92835, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States